Immunovia Dirección

Dirección controles de criterios 1/4

El CEO de Immunovia's es Jeff Borcherding, nombrado en Apr 2023, tiene una permanencia de 1.08 años. posee directamente un 0.77% de las acciones de la empresa, con un valor de $65.07K. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 4 años, respectivamente.

Información clave

Jeff Borcherding

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.1yrs
Participación del CEO	0.8%
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Jeff Borcherding (50 yo)

1.1yrs

Permanencia

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeff Borcherding	Global Chief Executive Officer & President	1.1yrs	sin datos	0.77% SEK 58.5k
Karin Liwendahl	Chief Financial Officer	2.1yrs	sin datos	sin datos
Karl Stone	Chief Operating Officer	1.2yrs	sin datos	sin datos
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.3yrs	sin datos	sin datos

1.2yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMMV.F no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Hongaard Andersen	Independent Chairman	4yrs	kr288.00k	sin datos
Hans Johansson	Independent Director	8.3yrs	kr280.00k	0.10% SEK 7.7k
Margaret Tempero	Member of Medical Advisory Board	7.9yrs	sin datos	sin datos
Diane Simeone	Member of Medical Advisory Board	7.8yrs	sin datos	sin datos
Michael Lofman	Independent Director	less than a year	sin datos	sin datos
Valerie Bogdan-Powers	Independent Director	less than a year	sin datos	sin datos
Stephen Pereira	Member of Medical Advisory Board	6.8yrs	sin datos	sin datos
Melissa Farina	Independent Director	less than a year	sin datos	sin datos
Martin Moller	Independent Director	3yrs	kr314.00k	sin datos

4.0yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de IMMV.F se considera experimentada (3.9 años de antigüedad promedio).

Immunovia Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Immunovia AB (Publ) Announces Board Changes

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad